Sudan's president is first Arab leader to visit Syria since crisis
AMMAN (Reuters) - Sudanese President Omar al-Bashir arrived in the Syrian capital Damascus on Sunday, the first such visit by an Arab leader since the start of the Syrian conflict, Syrian state media said. President Bashar al Assad welcomed him at the airport, official photos showed
AMMAN (Reuters) - Sudanese President Omar al-Bashir arrived in the Syrian capital Damascus on Sunday, the first such visit by an Arab leader since the start of the Syrian conflict, Syrian state media said.
President Bashar al Assad welcomed him at the airport, official photos showed. Many Arab countries have shunned Assad since the conflict that began early in 2011 after protests calling for his downfall swept Syria.
(Reporting by Suleiman Al-Khalidi; Editing by Catherine Evans)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
RIYADH (Reuters) - Saudi Arabia's former intelligence chief and ambassador to the United States, Prince Bandar bin Sultan bin Abdulaziz, slammed the Palestinian leadership for criticizing the decision of some Gulf states to normalise ties with Israel. In an interview with Saudi-owned Al Arabiya television aired on Monday, the prince labelled the Palestinian authorities' criticism a "transgression" and "reprehensible discourse".
By Marina Lammertyn and Miguel Lobianco BUENOS AIRES (Reuters) - Argentina has the world's highest rate of positive COVID-19 tests, according to Oxford-linked tracker Our World In Data, with nearly six out of 10 yielding an infection, a reflection of low testing levels and loose enforcement of lockdown rules. Argentina hit 809,728 confirmed cases on Monday, with an seven-day rolling average of around 12,500 new daily infections
LONDON (Reuters) - A combination of antiviral drugs usually used to treat HIV has no beneficial effect in patients hospitalised with COVID-19, a peer-reviewed study said on Monday, confirming the initial results of a large-scale randomised trial of the drug. British scientists running the RECOVERY trial at the University of Oxford in June said interim results had convincingly ruled out any meaningful benefit of lopinavir-ritonavir in lowering mortality among hospitalised patients